Viral Vector Formulation and Process Development Summit Europe

The timely Viral Vector Formulation and Process Development Summit Europe is the only definitive, end-to-end platform, uniting 60+ experts across up-and downstream process development, formulation, analytical development and regulatory disciplines from biopharma.

Across 3 days, hear from 18 viral vector pioneers working in cell and gene therapy and vaccine development, including Roche, VectorY, UCB, DiNAQOR and AviadoBio , to share their lessons learned and inspirations to overcome bottlenecks during scale-up and to reduce COGs.

Join thought leaders at this premium forum to increase your scale-up and manufacturing efficiency, deliver safe and cost-effective cures and treatments to larger patient populations.

URLs:
Website: https://go.evvnt.com/1679575-0?pid=10018
Tickets: https://go.evvnt.com/1679575-2?pid=10018
Brochure: https://go.evvnt.com/1679575-3?pid=10018

Prices:
Drug Developer Pricing - Conference Only: EUR 2799.00,
Solution Provider Rate - Conference Only: EUR 3399.00,
Academic Pricing - Conference Only: EUR 2399.00

Speakers: Frank Baganz, Associate Professor, University College London, Greta Jasulaityte, Senior Scientist - Process Development, MeiraGTx, Hilde van Tongeren, Head of Vector Generation, VectorY, Laurence Guianvarch, Head of Downstream Process Development, TaRGeT Inserm UMR1089, Marie Clincke, Gene Therapy Process Sciences Innovation and Partnership Leader, UCB S.A., Patrick Aldrin-Kirk, Chief Scientific Officer, rAAVen Therapeutics, Pepijn Burgers, Director - Scientific, Johnson and Johnson Services, Inc, Roland Pach, Global Expert - Cell Gene Therapy, Analytics Chemistry, Manufacturing and Controls, Roche, Takis Athanasopoulos, Vice President of Gene Therapy Research and Vector Technology, ViGeneron